Sign In
Sign Out
My Account
Subscribe
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
Special reports
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 27, 2005
View Archived Issues
Inhibition of MMPs may emerge as an antidiabetic strategy
Read More
AVI BioPharma commences phase II clinical trials of Resten-MP
Read More
New safety information for Celebrex in Canada
Read More
Lyrica now available in U.S.
Read More
Exelixis begins new phase I trials for three compounds
Read More
ReNeuron holds pre-IND meeting for ReN-001 stem cell therapy
Read More
Dimethaid Research shareholders approve name change to Nuvo Research
Read More
12-week results of ISA-247 phase III study in psoriasis
Read More
Phase II study evaluates CA4P triple combination therapy for ovarian cancer
Read More
SHEPHERD study of eculizumab for PNH completes enrollment
Read More
Ceregene begins phase I study of novel gene therapy for Parkinson's disease
Read More
AEG-35156 enters second phase I study
Read More
Laureate Pharma to supply Enobia with sPHEX metallopeptidase for phase I trials
Read More
First phase I results for insomnia drug NG2-73
Read More
Altastaph recommended to receive orphan medicinal product status in Europe
Read More
Arimoclomol begins phase II trial, receives fast track status
Read More
New therapeutics for cancer disclosed in recent patents
Read More
Novel agents for arthritis and related disorders reported
Read More
New anti-HIV agents described in recent patents
Read More
HCV RNA polymerase inhibitors claimed in Japan Tobacco patent
Read More
New data presented on AC-100
Read More
TGF-beta signaling pathways implicated in liraglutide's efficacy for type 2 diabetes
Read More
FK-614 improves insulin sensitivity both in the liver and in peripheral tissues
Read More
MicroRNA --a compelling target for anti-HCV therapy
Read More
BVT-2733 improves energy balance and glucose homeostasis in diet-induced obesity
Read More
DPP-IV inhibition does not affect physiological tissue microcirculation
Read More
Sildenafil and testosterone work synergistically in hypogonadal men
Read More
Good PK profile reported for AMG-162 in postmenopausal women
Read More
Topical BAL-10092 reduces skin inflammation in preclinical and human models
Read More
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe